OKT3 ENCEPHALOPATHY

被引：30

作者：

COLEMAN, AE

NORMAN, DJ

机构：

[1] OREGON HLTH SCI UNIV,DEPT MED TRANSPLANT MED,PORTLAND,OR 97201

[2] OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201

来源：

ANNALS OF NEUROLOGY | 1990年 / 28卷 / 06期

关键词：

D O I：

10.1002/ana.410280618

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

OKT3 therapy for induction immunosuppression in a patient who underwent renal transplantation produced obtundation and quadriparesis associated with computed tomographic scan evidence of brain edema. These findings resolved over 3 days with supportive therapy and OKT3 withdrawal. Copyright © 1990 American Neurological Association

引用

页码：837 / 838

页数：2

共 16 条

[1]

Norman DJ, The clinical role of OKT3, Immunol. Allergy Clin of North Am, 9, pp. 95-107, (1989)

[2]

Goldstein G, Norman DJ, Henell KR, Et al., Pharmacokinetic study of orthoclone OKT3 serum levels during treatment of acute renal allograft rejection, Transplantation, 46, pp. 587-589, (1988)

[3]

Emmons C, Smith J, Flanigan M, Cerebrospinal fluid inflammation during OKT3 therapy, Lancet, 2, pp. 510-511, (1986)

[4]

Martin MA, Massanari RM, Nghiem DD, Et al., Nosocomial aseptic meningitis associated with administration of OKT3, JAMA, 259, pp. 2002-2005, (1988)

[5]

Massanari R, Martin M, Smith J, Et al., Aseptic meningitis among kidney transplant recipients receiving a newly marketed murine monoclonal antibody preparation, MMWR, 35, pp. 551-552, (1986)

[6]

Thistlethwaite JR, Gaber AO, Haag BS, Et al., OKT3 treatment of steroid‐resistant renal allograft rejection, Transplantation, 43, pp. 176-184, (1987)

[7]

Thomas DM, Nicholls AJ, Feest TG, Riad H, OKT3 and cerebral oedema, Br Med J, 295, (1987)

[8]

Bristow MR, Gilbert EM, O'Connell JB, Et al., OKT3 monoclonal antibody in heart transplantation, Am J Kidney Dis, 11, pp. 135-140, (1988)

[9]

Chang T-W, Testa D, Kung PC, Et al., Cellular origin and interactions involved in γ‐interferon production induced by OKT3 monoclonal antibody, J Immunol, 128, pp. 585-589, (1982)

[10]

Chatenoud L, Therapeutic use of the OKT3 anti‐T cell monoclonal antibody: mode of action and side effects, Transplant Proc, 20, pp. 79-83, (1988)

← 1 2 →